Breast Cancer Clinical Trial
Official title:
A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer
RATIONALE: Zoledronate and ibandronate may prevent or help relieve bone pain and other
symptoms caused by bone metastases. It is not yet known whether zoledronate is more
effective than ibandronate in preventing bone problems caused by bone metastases due to
breast cancer.
PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works
compared to ibandronate in preventing bone problems in women with stage IV breast cancer
that has spread to the bone.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2006 |
Est. primary completion date | May 2006 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed stage IV breast cancer at primary diagnosis or at recurrence - Any T, any N, M1 - At least 1 dominant osteolytic or osteoblastic or mixed metastatic lesion outside any prior radiation field - Lesion measures = 1.0 cm by x-ray, CT scan, and/or MRI - Controlled asymptomatic brain metastases allowed - Controlled bone pain, defined as a physician/health care provider rating of = grade 2 pain-SELECT (Bone) on the NCI CTC for Adverse Events Version 3.0 rating scale, required - Current evidence of vertebral or nonvertebral fractures or spinal compression due to cancer, as determined by the treating physician, allowed - No Paget's disease of the bone - Estrogen receptor (ER) or progesterone receptor (PR) status known PATIENT CHARACTERISTICS: - Female patient - Menopausal status not specified - Zubrod performance status 0-2 - Creatinine normal - Creatinine clearance = 60 mL/min - Serum calcium < 12 mg/dL - Not pregnant or nursing - Fertile patients must use effective contraception - Must be able to receive IV medication and oral medication (i.e., must have physical integrity of the upper gastrointestinal tract) - No malabsorption syndrome - No primary hyperparathyroidism - No known history of aspirin-sensitive asthma - No other prior malignancy except for the following: - Adequately treated basal cell or squamous cell skin cancer - In situ cervical cancer - Adequately treated stage I or II cancer currently in complete remission - Any other cancer for which the patient has been disease-free for at least 5 years - No uncontrolled medical illness or infection, including, but not limited to, the following: - Unstable angina - Recent myocardial infarction - Life-threatening cardiac arrhythmia PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior bisphosphonates for metastatic bone disease - More than 28 days since prior aminoglycoside antibiotics - At least 28 days since prior oral bisphosphonates for osteoporosis - More than 6 months since prior bisphosphonates used for adjuvant therapy - Concurrent treatment, including chemotherapy, hormonal therapy, and/or biologic therapy for metastatic breast cancer allowed - No concurrent participation in another clinical treatment trial for this cancer unless the patient is no longer receiving the intervention and is in the follow-up phase of the other clinical trial |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Southwest Oncology Group | National Cancer Institute (NCI) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Skeletal-related events (SRE) | |||
Secondary | Change in patient's rating of worst pain as measured by the Brief Pain Inventory | |||
Secondary | Survival and time to first clinically apparent SRE | |||
Secondary | Tolerability and toxicity as measured by NCI CTCAE v3.0 | |||
Secondary | Changes in performance status |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |